Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Sedation With Third Molar Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiology (ASA) physical status I and II~* Four asymptomatic third molars indicated for removal~Exclusion Criteria:~* Clinical history or ECG evidence of:~  * cardiac dysrhythmia or heart block~ * ischemic heart disease~ * asthma~ * sleep apnea~ * impaired liver, renal, or mental function~* chronic sedative or analgesic use~* allergies to any of the study drugs~* history of pericoronal infection with third molars

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Dex plus midazolam (Type: ACTIVE_COMPARATOR): Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg i.v.
- Dex plus midazolam and ketamine (Type: ACTIVE_COMPARATOR): Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg and 0.25 mg/kg ketamine i.v.

Based on this trial design, predict the completion outcome and termination type (if applicable).